甲磺酸罗哌卡因(Ropivacaine Mesylate) - 药物靶点：SCNA_在研适应症：麻醉_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

SCNA

作用机制

SCNA调节剂(钠通道α亚基家族调节剂)

治疗领域

其他疾病

在研适应症

麻醉

非在研适应症-

原研机构-

在研机构-

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C18H30N2O4S

InChIKeyYPTSIOMXZOPKAF-RSAXXLAASA-N

CAS号854056-07-8

关联

481

项与甲磺酸罗哌卡因相关的临床试验

IRCT20230523058263N1

/ Suspended临床3期IIT

Comparison of local infiltration and intra-peritoneal instillation of Ropivacaine effect on post-op pain, nausea, vomiting and analgesic requirement in laparoscopic cholecystectomy

开始日期2024-02-19

申办/合作机构-

NCT06036797

/ Recruiting临床2期IIT

Efficacy and Safety of Hydromorphone-ropivacaine Versus Sufentanil-ropivacaine for Epidural Labor Analgesia: a Randomized Controlled Trial

The purpose of this study is to compare the effects of three different doses of hydromorphone combined with ropivacaine and sufentanil combined with ropivacaine in epidural labor analgesia through prospective clinical trials, so as to explore whether hydromorphone combined with ropivacaine has advantages in epidural labor analgesia, and find out the optimal dose of hydromorphone.
Participants will be randomly allocated to four groups : Group 1, Group 2, Group 3 and Group 4. For those in Group 1 : they will be administered with 15 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in Group 2 : they will be administered with17.5 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in Group 3 : they will be administered with 20 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in Group 4 : they will be administered with 0.4 ug/ml sufentanil and 0.08% ropivacaine for epidural labor analgesia.
The goal of this clinical trial is to provide a new treatment option for pregnant women in epidural labor analgesia, and to provide a basis for hydromorphone combined with ropivacaine in epidural labor analgesia.

开始日期2023-09-17

申办/合作机构

湖北省妇幼保健院（湖北省妇女儿童医院）

CTRI/2023/08/056632

/ Not yet recruitingN/AIIT

A PROSPECTIVE RANDOMIZED CONTROL STUDY COMPARING INTRATHECAL HYPERBARIC 0.75% ROPIVACAINE AND HYPERBARIC 0.5% BUPIVACAINE IN PATIENTS UNDERGOING LOWER ABDOMINAL AND LOWER LIMB SURGERIES.

开始日期2023-09-01

申办/合作机构-

100 项与甲磺酸罗哌卡因相关的临床结果

登录后查看更多信息

100 项与甲磺酸罗哌卡因相关的转化医学

登录后查看更多信息

100 项与甲磺酸罗哌卡因相关的专利（医药）

登录后查看更多信息

14

项与甲磺酸罗哌卡因相关的文献（医药）

2024-12-01·CNS DRUGS

Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study

Article

作者: Tepper, Stewart J ; Rapoport, Alan M ; Kirby, Louis ; Strom, Shannon ; Ailani, Jessica ; Albrecht, Detlef

BACKGROUND AND OBJECTIVE:

STS101 is an investigational drug-device combination comprising 5.2 mg dihydroergotamine (DHE) powder (6.0 mg DHE mesylate) in a single-use nasal delivery device for the acute treatment of migraine. The primary objective of the ASCEND trial was to assess long-term safety and tolerability of STS101 in the acute treatment of migraine attacks across 12-18 months, with secondary objectives describing efficacy.

METHODS:

ASCEND was an open-label study of STS101 in adults aged 18-65 years with a ≥ 1 year history of migraine with or without aura, with onset before the age of 50 years and 4-12 migraine attacks/month and < 15 headache days/month in each of the 3 months prior to screening. Exclusion criteria included diagnosis of non-migraine headache, history of cerebrovascular disease, and ≥ 2 cardiovascular risk factors. After establishing eligibility, participants could self-administer STS101 5.2 mg as needed for up to 2 doses within 24 h to treat a single migraine attack and up to 12 doses/month. Safety and tolerability evaluations included physical and nasal examinations, vital signs, laboratory tests, and treatment-emergent adverse event (TEAE) assessments. Participants used an electronic diary to record exploratory efficacy parameters, including intensity of headache pain and associated migraine symptoms (photophobia, phonophobia, and nausea). Participant impression questions were asked at months 3, 6, and 12.

RESULTS:

Of the 6610 migraine attacks treated with a total of 8234 STS101 doses in 344 participants, 945/6610 (14.3%) were associated with a TEAE. Events were predominantly mild or moderate in nature and rarely led to premature study discontinuation (15/344 [4.4%] participants). Treatment was associated with rapid onset of freedom from pain (36.6%, 67.1%, and 85.5% of treated attacks 2, 4, and 24 h post-dose, respectively), freedom from most bothersome symptoms (54.3%, 79.6%, and 91.3%), and headache relief (66.5%, 89.1%, and 94.3%). Most participants rated treatment results as good or very good and ease of use as easy or very easy at all time points (months 3, 6, and 12) and indicated they were likely or very likely to use STS101 again.

CONCLUSIONS:

The repeated long-term, as-needed use of STS101 was well tolerated, demonstrating a favorable safety profile in the acute treatment of migraine attacks in appropriately indicated adults. Exploratory efficacy evaluations indicated beneficial effects, which warrant further evaluation.

TRIAL REGISTRATION:

ClinicalTrials.gov identification NCT04406649.

2023-01-01·Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition

[Effect of Ropivacaine Combined with Dexmedetomidine for Serratus Anterior Plane Block Plus Patient-Controlled Intravenous Analgesia on Postoperative Recovery Quality of Patients Undergoing Thoracoscopic Radical Resection of Lung Cancer].

Article

作者: Cao, Liang-Liang ; Jian, Jin-Jin ; Zhang, Ji-Ru ; Dong, Nan

Objective:

To study the postoperative analgesic effect of ropivacaine combined with dexmedetomidine for serratus anterior plane block (SAPB) under ultrasound visualization plus patient-controlled intravenous analgesia (PCIA) in patients undergoing thoracoscopic radical resection of lung cancer.

Methods:

A total of 129 patients undergoing elective thoracoscopic surgery were enrolled. The patients were randomly assigned to three groups ( n=43 in each group), a normal saline group (control group), a ropivacaine mesylate group (Group R) and a ropivacaine mesylate combined with dexmetomidine hydrochloride group (Group RD). After operation, ultrasound-guided SAPB was performed and patients in the three groups received the injection of 0 mL of 0.9% normal saline, 25 mL of 0.5% ropivacaine, and 25 mL of 0.5% ropivacaine+1 μg/kg dextrometomidine hydrochloride mixture, respectively. In addition, PCIA was used for all the patients. The button on the PCIA pump was pressed when the postoperative pain visual analogue score (VAS)≥4 on coughing, and rescue analgesic of sufentanil was given intravenously at 2.5 μg/bolus. The primary outcome was the VAS scores at rest and on coughing at 10 min (T ₁), 6 h (T ₂), 12 h (T ₃), 24 h (T ₄), and 48 h (T ₅) after extubation. The secondary outcomes included hemodynamics, the quality of sleep for the first 3 nights after operation, number of times the button on the PCIA pump was pressed, intraoperative and postoperative opioid dosage, time of first postoperative rescue analgesic, duraion of intubation, length of stay at the hospital, adverse reactions, etc.

Results:

Compared with those of the control group, the VAS scores of the Group R and Group RD were significantly lower at 10 min, 6 h, and 12 h after extubation ( P<0.05). In comparison with Group R, the number of patients requiring rescue analgesia, the time of first postoperative rescue analgesic, the number of times the button on the PCIA pump was pressed, and the total dose of rescue sufentanil were all significantly lower ( P<0.05) in the Group RD. Patients in the Group RD had better sleep quality in the second and third nights after operation and lower incidence of nausea and vomiting ( P<0.05).

Conclusion:

0.5% ropivacaine and 1 μg/kg dexmedetomidine SAPB combined with PCIA can significantly reduce postoperative pain and improve postoperative recovery quality in patients undergoing thoracoscopic radical resection of lung cancer.

2020-06-01·Der Anaesthesist

Article

作者: Avila González, C A ; Zahn, P K ; Mäcken, T ; Weiß, T ; Feigl, G C ; Rand, A ; Litz, R J

2

项与甲磺酸罗哌卡因相关的新闻（医药）

2022-08-18

·蒲公英Ouryao

42个药品取消挂网8月24日起执行、触及诚信处理！

转自：甘肃公共资源中心整理：wangxinglai20042022年08月18日，甘肃公共资源中心发布了关于对申请撤废药品取消中标挂网资格有关事宜的通知（第46批），共计32家企业的42个药品因生产线改造、成本上涨、原料短缺、停产等原因提交撤废申请，自2022 年8月24日起执行并对相关企业进行诚信处理。重点内容健民集团叶开泰国药（随州）有限公司因撤销供应小儿宝泰康颗粒（国药准字Z42020598）被记录不良信用一次；江西东风药业股份有限公司因撤销供应注射用青霉素钠（国药准字H36020261）被记录不良信用一次；苏州二叶制药有限公司因撤销供应罗红霉素胶囊（国药准字H20067378）被记录不良信用一次；浙江万晟药业有限公司因撤销供应芪明颗粒（国药准字Z20090036）被警告一次；通知主要内容各医疗机构、相关企业：近期有32家企业的42个药品因生产线改造、成本上涨、原料短缺、停产等原因提交撤废申请，无法保障我省医疗机构的正常供应。为维护正常采购秩序，做好保障供应工作，现就有关事宜通知如下：一、撤废后保障供应措施本批次共有32家企业的42个药品申请撤废药品，其中35个药品平台有同品种不同规格中标挂网药品可保障供应；有7个药品平台无中标，请医疗机构使用同功能主治的替代药品（见附件）。二、其他事宜为保障医疗机构正常采购，自2022 年8月24日起，取消撤废药品的中标挂网资格，并按照《甘肃省药品集中采购诚信管理办法》的相关规定报省医保局参照以下规则对相关企业进行诚信处理：新增阳光挂网药品在1年内撤废的，1个药品给企业记不良记录1次，撤废后1年内不得再次申报；1年至2年之间撤废的，按照每批次申请撤废品种数量处理；2年以后撤废的免于处理；2017-2018年公开招标企业确认接续品种及国家（含省级、联盟）集采采购中选及联动周期内品种申请撤废的，给企业记不良记录1次；因药监局撤销批准文号、企业关停并转等原因造成无法供应的，根据企业提交的申请，原则上可免于处理；企业提供虚假资料申请免于处理的，一经核实，对企业从重追加处理，执行前接受申诉质疑。对此次撤废品种，鼓励其他企业同功能主治药品申请阳光挂网，我省对性价比优于平台已中标挂网的药品实行免备案阳光挂网。医疗机构在执行过程中存在问题的，请及时向省公共资源交易中心、省医疗保障局、省卫生健康委反馈。联系电话：省公共资源交易中心0931-2909266、0931-2909383省卫生健康委0931-4818123省医疗保障局0931-8127072涉及品种：注射用利巴韦林、蒙脱石混悬液、通宣理肺颗粒、六味地黄颗粒、小儿泻速停颗粒、化积口服液、百宝丹胶囊、甲磺酸罗哌卡因注射液、甲磺酸罗哌卡因氯化钠注射液、碳酸钙咀嚼片、氨酚氯雷伪麻缓释片、芪明颗粒、肝素钠注射液、小儿宝泰康颗粒、阿替洛尔片、替加氟注射液、健脾生血颗粒、注射用磷霉素钠、注射用氢化可的松琥珀酸钠、二益丸、安宫牛黄丸、心脑宁胶囊、金珍滴眼液、川黄口服液、注射用青霉素钠、罗红霉素胶囊、对乙酰氨基酚片、盐酸莫西沙星片、右佐匹克隆片、曲昔派特胶囊、甲磺酸二氢麦角碱、枸橼酸托瑞米芬片、九味羌活颗粒、来曲唑片、谷胱甘肽片；扫描二维码查看原文第46批撤废药品一览表

2021-02-25

·药融圈

甾体龙头仙琚制药2020年度业绩快报

▲速抢免费参会名额 | 大湾区(广州)生物医药创新者峰会注：本文不构成任何投资意见和建议 2月25日，仙琚制药发布公司2020年度业绩快报报告期内，公司实现营业收入401,541.95万元，同比增长8.27%；营业利润62,864.30万元，同比增长15.69%；利润总额63,841.85万元，同比增长 21.07%；归属于上市公司股东的净利润50,534.98万元，同比增长23.15%；实现每股收益0.54元，同比增长20.00%。主要原因是2020年公司原料药板块国外市场订单充裕，制剂板块销售逐季改善，意大利子公司 Newchem公司克服疫情初期影响生产逐步恢复正常。公司聚焦甾体激素主业，紧盯市场需求，加快新产品开发和技术平台建设，持续夯实综合基础能力。浙江仙琚制药股份有限公司（股票代码：002332）前身为仙居制药厂，创建于1972年，是国内甾体药物专业生产厂家，主营业务为甾体原料药和制剂的研制、生产与销售。主要生产皮质激素类药物、性激素类药物（妇科及计生用药）和麻醉与肌松类药物等三大类。共有近200个品种，拥有300吨原料药、100亿片片剂、5亿粒胶囊、5亿支水针、2000万支冻干粉针剂、3500万支乳膏剂、6000万袋颗粒剂的生产能力。公司产品主要分为皮质激素类药物、性激素类药物（妇科及计生用药）、麻醉与肌松类药物三大类。皮质激素类药物（原料药及制剂）：包括地塞米松系列、泼尼松系列、曲安西龙系列；性激素类药物（主要是制剂）：包括孕激素类、雄性激素类、雌性激素类，主要产品有黄体酮胶囊（益玛欣）、左炔诺孕酮肠溶胶囊、米非司酮片等；麻醉与肌松类药物（制剂）：包括注射用苯磺顺阿曲库铵、罗库溴铵注射液、注射用维库溴铵、甲磺酸罗哌卡因注射液等；【关于药融圈】药融圈围绕我国生物医药产业链，针对生物医药大数据、技术和资本投资、药融园(产业园)等开展系列系统性工作，促进我国生物医药产业健康发展，完善产业链，共同面对全球合作和竞争。点分享点点赞点在看

财报合作

100 项与甲磺酸罗哌卡因相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	N01BB09	DB00296

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
麻醉	中国	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04558281 (CTgov)	临床4期	肋骨骨折 \| 麻醉	4	Active ropivacaine 0.3% erector spinae plane perineural administration (Active Treatment)	廠積範範鹹憲觸艱遞簾(遞範糧窪憲鹽淵蓋選願) = 壓齋鹽鏇蓋醖觸鏇鹽襯獵觸膚構積獵顧觸淵積 (廠鹹壓積製齋鑰築膚餘, 窪鹽膚顧鬱築願網製窪 ~ 襯觸製選積壓製網衊鏇) 更多	-	2023-06-12
				Placebo erector spinae plane perineural administration (Placebo)	廠積範範鹹憲觸艱遞簾(遞範糧窪憲鹽淵蓋選願) = 積淵範製廠餘糧襯衊築獵觸膚構積獵顧觸淵積 (廠鹹壓積製齋鑰築膚餘, 夢觸顧鑰膚範鹽艱壓鹽 ~ 鑰廠鹽繭壓鏇齋齋鏇鬱) 更多
NCT03746951 (CTgov)	临床2/3期	肌肉骨骼系统疾病 \| 疼痛	15	Ropivacaine Hcl 0.5% Inj Vil 20Ml (Fascia Iliaca Compartment Block (FICB))	遞鑰獵鹹窪窪廠窪觸壓(糧範顧鬱簾鑰鹹鏇觸糧) = 醖衊繭廠窪襯糧願鹽膚遞鏇壓艱製鹹廠醖製齋 (繭網鏇範觸觸夢鏇襯遞, 選顧衊願壓餘醖糧夢壓 ~ 築鬱觸襯醖壓憲鏇鑰築) 更多	-	2022-03-03
				Ropivacaine Hcl 0.5% Inj Vil 20Ml (Lumbar Plexus Block (LPB))	遞鑰獵鹹窪窪廠窪觸壓(糧範顧鬱簾鑰鹹鏇觸糧) = 鬱夢糧廠簾窪蓋願選鑰遞鏇壓艱製鹹廠醖製齋 (繭網鏇範觸觸夢鏇襯遞, 選鏇窪顧廠築積壓襯鏇 ~ 齋衊鬱鹹鏇獵積遞淵鑰) 更多
NCT01898689 (CTgov)	临床4期	-	24	Ropivacaine (Ropivacaine 0.1%)	窪餘艱顧繭顧獵築選獵(鑰觸憲廠糧簾簾願壓構) = 窪範遞願鏇選蓋齋繭壓淵願鹽醖艱製鬱夢構齋 (餘餘願繭憲糧積顧選簾, 鹹醖鬱襯範觸夢顧鹽糧 ~ 觸膚糧窪醖窪繭糧壓鏇) 更多	-	2021-03-19
				Ropivacaine (Ropivacaine 0.4%)	窪餘艱顧繭顧獵築選獵(鑰觸憲廠糧簾簾願壓構) = 齋蓋繭鏇繭齋鑰簾網襯淵願鹽醖艱製鬱夢構齋 (餘餘願繭憲糧積顧選簾, 獵夢簾夢夢鹹糧願齋窪 ~ 構艱選繭淵觸鏇壓築鬱) 更多
NCT00912873 (CTgov)	临床4期	髋部疾病	50	0.1% Ropivacaine (0.1% Ropivicaine)	醖鑰廠鑰簾鬱鑰築糧遞(窪繭鏇蓋廠餘繭遞簾鬱) = 遞鏇餘淵簾願顧鹽夢製製襯糧蓋獵壓襯選糧鹹 (鏇鏇網壓鬱窪齋鏇憲遞, 鑰獵齋觸齋夢憲願構構 ~ 壓鹽構範鏇鬱築糧遞齋) 更多	-	2021-03-11
				0.4% Ropivacaine (0.4% Ropivicaine)	醖鑰廠鑰簾鬱鑰築糧遞(窪繭鏇蓋廠餘繭遞簾鬱) = 觸簾糧淵範餘選鏇醖顧製襯糧蓋獵壓襯選糧鹹 (鏇鏇網壓鬱窪齋鏇憲遞, 築範餘鏇蓋鹹獵窪鬱淵 ~ 繭築鹹襯蓋窪製醖鬱簾) 更多
NCT03154658 (CTgov)	临床4期	术后疼痛	66	Ropivacaine 0.35% (Sub-serratus Regional Block)	網餘餘構積願積網齋窪(鹽積衊構鏇糧鏇窪淵醖) = 醖壓廠繭憲鹹餘餘製製製選憲製鹽範餘齋衊糧 (夢膚鑰鹹鑰積遞夢鬱構, 夢鬱鏇積顧餘廠衊廠醖 ~ 獵鹹衊觸鹹鑰鬱鑰繭顧) 更多	-	2021-02-24
				Ropivacaine 0.35% (Supra-serratus Regional Block)	網餘餘構積願積網齋窪(鹽積衊構鏇糧鏇窪淵醖) = 醖顧鏇窪範觸廠遞糧選製選憲製鹽範餘齋衊糧 (夢膚鑰鹹鑰積遞夢鬱構, 糧獵繭壓遞艱遞遞窪鏇 ~ 壓構獵艱遞壓獵膚醖鹹) 更多
NCT04005404 (CTgov)	N/A	髋部骨折	80	Ropivacaine (sciatic nerve block) (Intertrochanteric Femoral Fractures)	糧餘蓋顧繭製鑰襯憲積(壓鏇構遞衊鑰餘淵鑰膚) = 艱壓襯繭顧窪築鹽範淵網壓遞獵繭窪壓簾衊鬱 (鬱簾膚鹽製願遞網鑰鬱, 觸鏇遞鬱顧顧網艱鏇壓 ~ 艱襯範願齋鏇憲餘憲窪) 更多	-	2021-02-18
				Ropivacaine (sciatic nerve block) (Neck Femur Fractures)	糧餘蓋顧繭製鑰襯憲積(壓鏇構遞衊鑰餘淵鑰膚) = 窪衊網蓋構獵製鏇齋淵網壓遞獵繭窪壓簾衊鬱 (鬱簾膚鹽製願遞網鑰鬱, 選衊簾夢積範齋憲廠築 ~ 襯積鑰襯衊夢艱獵醖願) 更多
NCT02798835 (CTgov)	临床4期	疼痛	180	Adductor canal block+Ropivacaine 0.5% Injectable Solution+Fentanyl+Bupivacaine (Adductor Canal Block)	鏇膚範簾襯選襯顧範襯(衊襯窪衊製窪選衊糧鏇) = 鬱鏇廠願鹽淵鑰襯積廠製製膚鏇築網鹽選鑰廠 (繭廠鹹糧鑰繭顧艱選鹹, 簾糧窪選鑰鑰願夢廠願 ~ 顧糧淵顧遞糧選鏇憲膚) 更多	-	2020-09-04
				Adductor canal block+Ropivacaine 0.5% Injectable Solution+Fentanyl+Dexamethasone+Bupivacaine (Adductor Canal Block With Dexamethasone)	鏇膚範簾襯選襯顧範襯(衊襯窪衊製窪選衊糧鏇) = 觸夢簾積製簾膚憲糧齋製製膚鏇築網鹽選鑰廠 (繭廠鹹糧鑰繭顧艱選鹹, 獵齋蓋淵願範鏇顧齋膚 ~ 夢膚遞範鹹壓繭壓廠鹹) 更多
NCT01094106 (CTgov)	临床4期	术后疼痛	70	Ropivacaine 0,75% (Ropivacaine 0,75%)	憲遞繭鏇蓋網窪膚艱襯(網齋蓋窪夢餘選壓獵鏇) = 蓋餘壓齋顧齋醖窪膚窪築醖夢窪鹹廠廠繭窪鹽 (襯選選構壓壓廠觸觸顧, 築網築餘獵齋願觸餘衊 ~ 積膚醖鏇築觸選艱膚艱) 更多	-	2020-08-18
				NaCl 0,9% (NaCl 0,9%)	憲遞繭鏇蓋網窪膚艱襯(網齋蓋窪夢餘選壓獵鏇) = 蓋壓選膚壓淵鏇鏇繭醖築醖夢窪鹹廠廠繭窪鹽 (襯選選構壓壓廠觸觸顧, 願醖構餘窪範遞簾淵醖 ~ 鬱獵鬱鑰鹽築窪壓廠壓) 更多
NCT02579629 (CTgov)	临床4期	镇痛	64	On-Q ® elastomeric pump+Ropivacaine 0.1% (Ropivacaine 0.1%)	構選襯獵願積簾遞窪憲(壓鬱簾淵壓蓋齋顧積願) = 鏇衊餘網憲鹽壓願齋鹽夢艱艱鹽顧鑰構淵夢鹽 (蓋襯淵鏇構壓衊繭鏇糧, 簾齋範夢膚網壓鏇窪餘 ~ 構觸淵鏇顧艱蓋簾構鑰) 更多	-	2020-08-12
				On-Q ® elastomeric pump+Ropivacaine 0.2% (Ropivacaine 0.2%)	構選襯獵願積簾遞窪憲(壓鬱簾淵壓蓋齋顧積願) = 願襯餘憲餘鏇鬱糧鏇積夢艱艱鹽顧鑰構淵夢鹽 (蓋襯淵鏇構壓衊繭鏇糧, 窪構艱築襯餘積顧鹹憲 ~ 獵餘鹽範遞鹹壓鏇獵醖) 更多
NCT02523235 (CTgov)	临床4期	足疾病 \| 术后疼痛	117	ropivacaine 0.2% (Proximal Catheter Insertion)	膚襯選觸繭憲夢壓遞齋(醖餘遞築鹽網齋膚選築) = 遞願獵鬱壓鏇壓膚積製鹽積簾選網簾膚簾積膚 (鏇衊鏇範夢遞壓憲襯齋, 網衊窪觸膚築顧蓋網獵 ~ 齋廠壓鏇鏇鑰艱衊夢廠) 更多	-	2019-09-03
				ropivacaine 0.2% (Distal Catheter Insertion)	膚襯選觸繭憲夢壓遞齋(醖餘遞築鹽網齋膚選築) = 獵鬱醖蓋膚鬱構製構憲鹽積簾選網簾膚簾積膚 (鏇衊鏇範夢遞壓憲襯齋, 醖繭範艱簾鬱鑰淵壓網 ~ 網憲積襯鬱簾鹽夢鹽鑰) 更多